A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.
Zhang N, Zhang G, Liu N, Lin W, Ji S, Zheng M, Chen K, Liang X, Li G, Ma Y, Zhu J, Niu T, Li LL, Li J, Wei YQ, Yang SY.
Zhang N, et al.
Oncotarget. 2017 Dec 1;8(67):111495-111507. doi: 10.18632/oncotarget.22847. eCollection 2017 Dec 19.
Oncotarget. 2017.
PMID: 29340070
Free PMC article.